-
RACE study results released, eltrombopag combination therapy is expected to become the new standard of treatment for severe aplastic anemia
Time of Update: 2022-01-25
Studies have shown that in patients with severe aplastic anemia, the addition of eltrombopag to IST alone resulted in higher quality and faster remission in patients with SAA/vSAA without increased toxicity .
-
5-year long-term effect observation of BioMarin's hemophilia gene therapy phase III clinical trial, with positive data
Time of Update: 2022-01-23
Trial results showed that in 112 subjects (median follow-up of 110 weeks), valoctocogene roxaparvovec reduced the patient's annual bleeding rate (ABR) by 85% compared to a baseline value of 4.
-
Leuk Res: Docepastat (DSTAT), a CXCL12/CXCR4 inhibitor, in combination with azacitidine for the treatment of hypomethylating agent-refractory AML and MDS
Time of Update: 2022-01-23
A research team conducted a pilot study of adding DSTAT to azacitidine in patients with AML or MDS who had not responded to or had relapsed to prior hypomethylating drug therapy, hypothesizing that DSTAT might improve response rates .
-
TRANSFUSION: Platelet-to-erythrocyte ratio and mortality in patients with hemorrhagic trauma: a systematic review and meta-analysis
Time of Update: 2022-01-23
event = number of patients affected, total = total number of patients, high = group with the highest platelet:RBC ratio, low = group with the lowest platelet:RBC ratio, MH = Mantel-HaenszelFigure 3: High platelet:erythrocyte ratio has no effect on thromboembolic events or organ failure in trauma patients in randomized controlled trials .
-
Clin Exp Immunol: Interferon-Gamma- and perforin-positive T cells in acquired aplastic anemia predict response to immunosuppressive therapy
Time of Update: 2022-01-23
Figure 1: Representative flow cytometry plots showing results in healthy controls, untreated non-severe aplastic anemia (NSAA), severe aplastic anemia (SAA), and very severe aplastic anemia ( Median percentage and absolute numbers of IFN-γ and perforin-producing CD5 T cells in patients with VSAA) .
-
Cancers: Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differentially affected by tyrosine kinase inhibitors
Time of Update: 2022-01-23
(A) Newly diagnosed chronic myeloid leukemia (CML) patients were neutral when stimulated with 5 μM ionomycin (IO) or dimethyl sulfoxide (DMSO) compared to age- and sex-matched healthy controls Granulocyte extracellular traps (NETs) were formed for 2 hours .
-
Leuk Res: High Bax/Bcl-2 ratio is associated with good prognosis and better survival in B-cell chronic lymphocytic leukemia patients
Time of Update: 2022-01-22
Determination of the Bax/Bcl-2 ratio may be a good predictive tool for identifying the prognosis and prognosis of patients with chronic lymphocytic leukemia (CLL) to determine the timing and type of treatment, therefore, a prospective study of 100 newly diagnosed CLL patients was performed.
-
J. Clin. Med: Long-term efficacy and safety of ibrutinib in patients with CLL: a real-life experience.
Time of Update: 2022-01-22
In addition to the information collected in clinical trials, there is little data on the real-life use of ibrutinib, and only a few studies have mature data on its long-term outcomes, survival, and adherence to treatment .
-
Blood: Clinical benefit of ruxolitinib targeted inhibition of JAK/STAT in patients with T-cell lymphoma
Time of Update: 2022-01-22
Expression of immunophosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, correlates with responsiveness to ruxolitinib treatment in <25% of tumor cells Phosphorylated S6, a PI3 kinase or markers of mitogen-activated protein kinase activation) expression in <25% of tumor cells correlated with responsiveness to ruxolitinib treatmentIn conclusion, this study demonstrates that ruxolitinib has antitumor activity in various PTCL subtypes, suggesting that PTCL patients may be able to employ precision therapeutic strategies for JAK/STAT inhibition .
-
PNAS: Low temperature atmospheric plasma (CAP) "gas" for leukemia treatment?
Time of Update: 2022-01-22
Tri-CAP-treated tumor-bearing mice had reduced tumor growth and prolonged survival (Source: PNAS Journal)Conventional ROS-generating therapies, including radiotherapy, usually rely on high levels of ROS to induce direct cancer cell death, but at the same time, tumor survival-related pathways are activated, resulting in limited efficacy .
-
AJH: PD-L1 overexpression is associated with JAK2-V617F mutational burden and with 9p uniparental disomy in myeloproliferative neoplasms.
Time of Update: 2022-01-22
Figure 1: RNA-sequencing shows upregulation of PD-L1 expression in myeloid cells from patients with polycythemia vera and the role of chromosome 9pUPD in the upregulation of PD-L1 expression in MPNs. By RNA-sequencing of granulocytes from 113 MPN patients, we found that PD-L1 expression was highest in polycythemia vera patients and that PDL1 expression correlated with JAK2-V617F mutational burden (R=0.
-
Crit Care: Hyperoxemia associated with reduced mortality in patients with sepsis/septic shock
Time of Update: 2022-01-22
CONCLUSIONS: PaO2 higher than 100 mmHg was associated with 90-day mortality, ICU stay and intubation time in patients with severe postoperative sepsis/septic shock .
PaO2 higher than 100 mmHg was associated with 90-day mortality, ICU stay and intubation time in patients with severe postoperative sepsis/septic shock .
-
NEJM: Addition of Eltrombopag to Immunosuppressive Therapy for Severe Aplastic Anemia
Time of Update: 2022-01-22
immunityEltrombopag improves efficacy of standard immunosuppressive therapy including equine antithymocyte globulin [ATG] and cyclosporine in patients with severe aplastic anemia , a single-arm phase 1-2 study shows .
Eltrombopag improves the efficacy of standard immunosuppressive therapy, including equine antithymocyte globulin [ATG] and cyclosporine, in patients with severe aplastic anemia .
-
Blood: Influence of residual disease status on survival of CLL patients treated with different regimens
Time of Update: 2022-01-22
PFS was not significantly worse in patients with detected MRDTaken together, the results of this study support the use of MRD as a surrogate endpoint for PFS in patients treated with FCR .
-
Biomarker screening and validation for differentiating bloodstream infection from adult Still's disease: a prospective cohort study
Time of Update: 2022-01-22
Peptidoglycan bacterial cell wall teichoic acid polysaccharide lipoteichoic acid lipopolysaccharide surface antigenAOSD is a rare, systemic autoinflammatory disorder of unknown origin with high fever, transient rash, arthralgia , sore throat, swollen lymph nodes , hepatosplenomegaly, and myalgia .
-
JAMA: Anticoagulation can be shortened to 6 weeks in patients under 21 years of age with induced venous thromboembolism
Time of Update: 2022-01-22
Original Source: Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism The Kids-DOTT Randomized Clinical Trial.
-
Stroke: Clinical significance of endogenous deoxyribonuclease activity and cell-free DNA in patients with acute ischemic stroke
Time of Update: 2022-01-22
After adjusting for confounding factors (Essen Stroke Risk Score, NIH Stroke Scale, and gender), 7-day cfDNA levels were independently associated with clinical outcomes, especially mortality (adjusted odds ratio 3.
Endogenous Deoxyribonuclease Activity and Cell-Free Deoxyribonucleic Acid in Acute Ischemic Stroke: A Cohort Study .
-
Acta Haematol: Successful treatment of vaccine-induced immune thrombotic thrombocytopenia in a 26-year-old female patient
Time of Update: 2022-01-21
Here, the Journal of Acta Haematol reports on a 26-year-old female patient who developed bilateral deep vein thrombosis (DVT) and thrombocytopenia in the lower legs after vaccination with ChAdOx1nCov-19, including fondaparinux, apixaban After failure of initial anticoagulation regimens including danaparin and danaparin, the patient was successfully treated with high-dose intravenous immune globulin in combination with parental anticoagulation with argatroban .
-
J Thromb Haemost: Thrombomodulin (THBD) Gene Variation and Thrombosis Risk
Time of Update: 2022-01-21
thrombusThe aim of this study was to determine the risk of thrombosis in individuals with rare and common THBD variants in a large middle-aged and elderly population .
15630Original Source: Thrombomodulin (THBD) gene variants and thrombotic risk in a population-based cohort study Leave a comment here
-
J INTERN MED: What is the risk of thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica?
Time of Update: 2022-01-21
The purpose of this study was to compare the risk of thromboembolic events and retinal vascular occlusion in patients with osteoarthritis (OA) with GCA and / or PMR .
